Accustem Sciences (ACUT) Accumulated Expenses (2021 - 2026)
Accustem Sciences (ACUT) posted quarterly Accumulated Expenses of $1875.0 for Q1 2026, down 98.73% year-over-year from $147900.0 in Q1 2025, and little changed quarter-over-quarter from $1875.0 in Q4 2025.
Accustem Sciences (ACUT) Accumulated Expenses (2021 - 2026) Analysis & Trends
Accustem Sciences (ACUT) has reported Accumulated Expenses for 6 consecutive years, with $1875.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Expenses fell 98.73% year-over-year to $1875.0; the TTM figure through Mar 2026 stood at $1875.0 (down 98.73% YoY), while the FY2025 annual figure was $1875.0, down 98.86% from the prior year.
- Accumulated Expenses was little changed at $1875.0 in Q1 2026 per ACUT's latest filing, from $1875.0 in the prior quarter.
- Across five years, Accumulated Expenses topped out at $723933.0 in Q1 2023 and bottomed at $1875.0 in Q4 2025.
- Historically, Accumulated Expenses has averaged $228052.4 across 5 years, with a median of $164053.0 in 2024.
- Annual changes were most pronounced in 2023 — Accumulated Expenses jumped 567.59% — and 2025, when it slumped 98.86%.
- Accustem Sciences' Accumulated Expenses stood at $518625.0 in 2022, then plunged by 69.84% to $156434.0 in 2023, then advanced by 4.87% to $164053.0 in 2024, then plunged by 98.86% to $1875.0 in 2025, then changed by 0.0% to $1875.0 in 2026.
- Business Quant data shows ACUT's Accumulated Expenses at $1875.0 in Q1 2026, $1875.0 in Q4 2025, and $149774.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Accustem Sciences | 2.57 Mn | 2.56 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,875.00 |
| Dec 31, 2025 | 1,875.00 |
| Sep 30, 2025 | 149,774.00 |
| Jun 30, 2025 | 153,836.00 |
| Mar 31, 2025 | 147,900.00 |
| Dec 31, 2024 | 164,053.00 |
| Sep 30, 2024 | 164,053.00 |
| Jun 30, 2024 | 154,898.00 |
| Mar 31, 2024 | 219,567.00 |
| Dec 31, 2023 | 156,434.00 |
| Sep 30, 2023 | 272,603.00 |
| Jun 30, 2023 | 371,539.00 |
| Mar 31, 2023 | 723,933.00 |
| Dec 31, 2022 | 518,625.00 |
| Sep 30, 2022 | 349,183.00 |
| Jun 30, 2022 | 218,303.00 |
| Mar 31, 2022 | 108,440.00 |
| Dec 31, 2021 | 123,181.00 |